Cover Image
市場調查報告書

Apitope International NV - 產品平台分析

Apitope International NV - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 253715
出版日期 內容資訊 英文 26 Pages
訂單完成後即時交付
價格
Back to Top
Apitope International NV - 產品平台分析 Apitope International NV - Product Pipeline Review - 2015
出版日期: 2015年08月31日 內容資訊: 英文 26 Pages
簡介

Apitope International NV是總公司設立於比利時的生物科技企業,正在從事治療過敏和自體免疫疾病的醫藥品開發。正在開發針對多發性硬化症和巴塞杜氏病,葡萄薄膜炎等疾病所用之復原免疫系統平衡的高選擇性胜肽之新治療藥候補物質。

本報告提供Apitope International NV的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃相關等資訊。

目錄

Apitope International NV 基本資料

  • Apitope International NV 概要
  • 主要資訊
  • 企業資料

Apitope International NV :R&D概要

  • 主要的治療範圍

Apitope International NV :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Apitope International NV :開發中產品概況

  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

Apitope International NV :藥物簡介

  • ATXF-8117
  • ATXGD-459
  • ATXMS-2
  • ATXMS-3
  • ATXUV-1
  • ATXUV-2

Apitope International NV :開發平台分析

  • 標的別
  • 各分子類型
  • 各作用機制

Apitope International NV :最新的開發平台資訊

Apitope International NV :總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07371CDB

Summary

Global Markets Direct's, 'Apitope International NV - Product Pipeline Review - 2015', provides an overview of the Apitope International NV's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Apitope International NV's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Apitope International NV including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Apitope International NV's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Apitope International NV's pipeline products

Reasons to buy

  • Evaluate Apitope International NV's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Apitope International NV in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Apitope International NV's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Apitope International NV and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Apitope International NV
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Apitope International NV and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Apitope International NV Snapshot
    • Apitope International NV Overview
    • Key Information
    • Key Facts
  • Apitope International NV - Research and Development Overview
    • Key Therapeutic Areas
  • Apitope International NV - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Apitope International NV - Pipeline Products Glance
    • Apitope International NV - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Apitope International NV - Drug Profiles
    • ATXF-8117
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ATXGD-459
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ATXMS-2
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ATXMS-3
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ATXUV-1
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ATXUV-2
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Apitope International NV - Pipeline Analysis
    • Apitope International NV - Pipeline Products by Target
    • Apitope International NV - Pipeline Products by Molecule Type
    • Apitope International NV - Pipeline Products by Mechanism of Action
  • Apitope International NV - Recent Pipeline Updates
  • Apitope International NV - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Apitope International NV, Key Information
  • Apitope International NV, Key Facts
  • Apitope International NV - Pipeline by Indication, 2015
  • Apitope International NV - Pipeline by Stage of Development, 2015
  • Apitope International NV - Monotherapy Products in Pipeline, 2015
  • Apitope International NV - Out-Licensed Products in Pipeline, 2015
  • Apitope International NV - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Apitope International NV - Preclinical, 2015
  • Apitope International NV - Discovery, 2015
  • Apitope International NV - Pipeline by Target, 2015
  • Apitope International NV - Pipeline by Molecule Type, 2015
  • Apitope International NV - Pipeline Products by Mechanism of Action, 2015
  • Apitope International NV - Recent Pipeline Updates, 2015
  • Apitope International NV, Subsidiaries

List of Figures

  • Apitope International NV - Pipeline by Top 10 Indication, 2015
  • Apitope International NV - Pipeline by Stage of Development, 2015
  • Apitope International NV - Monotherapy Products in Pipeline, 2015
  • Apitope International NV - Pipeline by Top 10 Molecule Type, 2015
Back to Top